Niagen Bioscience reported strong e-commerce growth in its second quarter of 2026, with TrueNiagen website sales up 23% year-over-year and Amazon sales up 10%, a figure that would have been approximately 19% absent a temporary platform issue. The company's China cross-border channel surpassed its full-year 2025 revenue by May 2026, signaling significant growth potential in that market. Net income declined to $1 million, or $0.01 per diluted share, compared to $0.05 per diluted share a year earlier, while selling and marketing expenses rose to 34% of net sales from 26.4%. The company holds $66.7 million in cash with no debt and a $14.6 million remaining share repurchase authorization, and it is advancing its pharmaceutical pipeline with NB4168, which has received rare pediatric disease and orphan drug designations and could qualify for a transferable priority review voucher worth approximately $150 million.
Niagen Bioscience, Inc.Strong e-commerce growth and China cross-border sales exceeding full-year 2025 indicate robust demand.
Amazon.com Inc
